Compare Stocks: EQ, CCCC, ARCT, and EBS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$11.12 -7.6%	$13.09	$5.50 ▼ $24.17	$341.93M	2.48	816,795 shs	588,809 shs
CCCC C4 Therapeutics	$2.61 -6.1%	$3.53	$1.69 ▼ $5.17	$342.01M	3.07	2.37 million shs	3.09 million shs
EBS Emergent Biosolutions	$6.90 -0.2%	$6.05	$4.36 ▼ $14.06	$354.30M	2.28	1.14 million shs	761,078 shs
EQ Equillium	$1.30 -1.5%	$1.99	$0.76 ▼ $3.54	$83.70M	1.93	760,050 shs	263,692 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-7.56%	-12.92%	-27.27%	+79.94%	-47.67%
CCCC C4 Therapeutics	-6.12%	-7.45%	-23.91%	-27.09%	+29.21%
EBS Emergent Biosolutions	-0.72%	-2.60%	+8.48%	-10.16%	-24.36%
EQ Equillium	-1.52%	-6.47%	-38.10%	-48.00%	+4.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$11.12 -7.6%	$13.09	$5.50 ▼ $24.17	$341.93M	2.48	816,795 shs	588,809 shs
CCCC C4 Therapeutics	$2.61 -6.1%	$3.53	$1.69 ▼ $5.17	$342.01M	3.07	2.37 million shs	3.09 million shs
EBS Emergent Biosolutions	$6.90 -0.2%	$6.05	$4.36 ▼ $14.06	$354.30M	2.28	1.14 million shs	761,078 shs
EQ Equillium	$1.30 -1.5%	$1.99	$0.76 ▼ $3.54	$83.70M	1.93	760,050 shs	263,692 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-7.56%	-12.92%	-27.27%	+79.94%	-47.67%
CCCC C4 Therapeutics	-6.12%	-7.45%	-23.91%	-27.09%	+29.21%
EBS Emergent Biosolutions	-0.72%	-2.60%	+8.48%	-10.16%	-24.36%
EQ Equillium	-1.52%	-6.47%	-38.10%	-48.00%	+4.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.67	Moderate Buy	$22.00	97.84% Upside
CCCC C4 Therapeutics	2.50	Moderate Buy	$8.50	225.67% Upside
EBS Emergent Biosolutions	2.17	Hold	$10.00	45.03% Upside
EQ Equillium	2.91	Moderate Buy	$7.57	482.42% Upside

Current Analyst Ratings Breakdown

Latest EQ, CCCC, ARCT, and EBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	EQ Equillium	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$6.00
10/9/2026	ARCT Arcturus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$13.00 ➝ $19.00
10/9/2026	CCCC C4 Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$10.00
9/24/2026	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/24/2026	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$23.00 ➝ $20.00
9/24/2026	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$8.00 ➝ $20.00
9/21/2026	EQ Equillium	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/9/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
9/4/2026	EQ Equillium	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$12.00
9/2/2026	ARCT Arcturus Therapeutics	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$41.00
8/21/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D-) ➝ Sell (D)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	3.85	N/A	N/A	$7.53 per share	1.48
CCCC C4 Therapeutics	$35.95M	8.93	N/A	N/A	$2.65 per share	0.98
EBS Emergent Biosolutions	$742.90M	0.48	$3.65 per share	1.89	$9.95 per share	0.69
EQ Equillium	$41.10M	2.01	N/A	N/A	$0.47 per share	2.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	9.32	N/A	-22.95%	16.35%	6.17%	11/4/2026 (Estimated)
EQ Equillium	-$22.40M	-$0.20	N/A	N/A	N/A	N/A	-41.15%	-38.29%	11/12/2026 (Estimated)

Latest EQ, CCCC, ARCT, and EBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	EQ Equillium	-$0.05	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q3 2026	ARCT Arcturus Therapeutics	-$0.6866	N/A	N/A	N/A	$8.00 million	N/A
11/5/2026	Q3 2026	CCCC C4 Therapeutics	-$0.2010	N/A	N/A	N/A	$8.85 million	N/A
11/4/2026	Q3 2026	EBS Emergent Biosolutions	-$0.37	N/A	N/A	N/A	$123.22 million	N/A
8/13/2026	Q2 2026	EQ Equillium	-$0.0540	-$0.04	+$0.0140	-$0.04	N/A	N/A
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
CCCC C4 Therapeutics	N/A	5.45	5.45
EBS Emergent Biosolutions	1.70	5.42	2.95
EQ Equillium	N/A	23.40	23.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
CCCC C4 Therapeutics	78.81%
EBS Emergent Biosolutions	78.40%
EQ Equillium	27.05%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
CCCC C4 Therapeutics	5.60%
EBS Emergent Biosolutions	6.00%
EQ Equillium	17.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	111	28.42 million	23.36 million	Optionable
CCCC C4 Therapeutics	104	123.03 million	116.14 million	Optionable
EBS Emergent Biosolutions	900	51.27 million	48.20 million	Optionable
EQ Equillium	14	63.41 million	52.10 million	Not Optionable

EQ, CCCC, ARCT, and EBS Headlines

Recent News About These Companies

This biotech stock has a massive upside, Roth says

October 14 at 2:37 PM | cantechletter.comC

Equillium (NASDAQ:EQ) Given "Outperform" Rating at Leerink Partners

October 12 at 8:41 AM | marketbeat.com

Equillium, Inc. Receives Australian Regulatory Clearance to Initiate First-In-Human Clinical Trial of Eq504

October 7, 2026 | marketscreener.comM

Equillium Gains Australian Nod For Phase 1 Study Of EQ504; Dosing In Nov'26

October 7, 2026 | rttnews.com

Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference

October 6, 2026 | globenewswire.com

Equillium (NASDAQ: EQ) clears Australia for EQ504 dosing

October 6, 2026 | americanbankingnews.com

Equillium Gets Australian Clearance for Phase 1 Trial of Ulcerative Colitis Drug Candidate EQ504

October 5, 2026 | finance.yahoo.com

Equillium Advances EQ504 With Phase 1 Trial Clearance

October 5, 2026 | tipranks.com

Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504

October 5, 2026 | globenewswire.com

Equillium Announces Poster Presentations at the 7th International AHR Conference

September 29, 2026 | globenewswire.com

Equillium, Inc. (NASDAQ:EQ) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 29, 2026 | marketbeat.com

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

September 27, 2026 | marketbeat.com

Equillium en el Foro Virtual de Inmunología de Stifel 2026

September 24, 2026 | mx.investing.com

Equillium (NASDAQ:EQ) Lowered to "Sell" Rating by Wall Street Zen

September 19, 2026 | marketbeat.com

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

September 16, 2026 | markets.businessinsider.com

Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum

September 16, 2026 | globenewswire.com

EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon

September 14, 2026 | reuters.com

Equillium to Participate in Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 13, 2026 | globenewswire.com

Equillium: The Market Seems To Have Already Priced In Phase 1 Success

July 24, 2026 | seekingalpha.com

Equillium (EQ) Gets a Buy from Oppenheimer

July 6, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EQ, CCCC, ARCT, and EBS Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$11.12 -0.91 (-7.56%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$11.11 -0.01 (-0.09%)

As of 10/14/2026 07:30 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

C4 Therapeutics NASDAQ:CCCC

$2.61 -0.17 (-6.12%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$2.64 +0.02 (+0.96%)

As of 04:00 AM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Emergent Biosolutions NYSE:EBS

$6.90 -0.02 (-0.22%)

Closing price 10/14/2026 03:59 PM Eastern

Extended Trading

$6.85 -0.04 (-0.65%)

As of 04:04 AM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Equillium NASDAQ:EQ

$1.30 -0.02 (-1.52%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$1.32 +0.01 (+1.15%)

As of 10/14/2026 07:30 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EQ, CCCC, ARCT, and EBS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EQ, CCCC, ARCT, and EBS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EQ, CCCC, ARCT, and EBS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EQ, CCCC, ARCT, and EBS Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

C4 Therapeutics NASDAQ:CCCC

Emergent Biosolutions NYSE:EBS

Equillium NASDAQ:EQ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EQ, CCCC, ARCT, and EBS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EQ, CCCC, ARCT, and EBS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EQ, CCCC, ARCT, and EBS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EQ, CCCC, ARCT, and EBS Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

C4 Therapeutics NASDAQ:CCCC

Emergent Biosolutions NYSE:EBS

Equillium NASDAQ:EQ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools